Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2009 Jun 23;10625:10338-42. doi: 10.1073/pnas.0901249106.
Show Gene links
Show Anatomy links
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M.
???displayArticle.abstract???
Genome-wide association studies (GWAS) have successfully identified common single nucleotide polymorphisms (SNPs) associated with a wide variety of complex diseases, but do not address gene function or establish causality of disease-associated SNPs. We recently used GWAS to identify SNPs in a genomic region on chromosome 4 that associate with serum urate levels and gout, a consequence of elevated urate levels. Here we show using functional assays that human ATP-binding cassette, subfamily G, 2 (ABCG2), encoded by the ABCG2 gene contained in this region, is a hitherto unknown urate efflux transporter. We further show that native ABCG2 is located in the brush border membrane of kidneyproximal tubule cells, where it mediates renal urate secretion. Introduction of the mutation Q141K encoded by the common SNP rs2231142 by site-directed mutagenesis resulted in 53% reduced urate transport rates compared to wild-type ABCG2 (P < 0.001). Data from a population-based study of 14,783 individuals support rs2231142 as the causal variant in the region and show highly significant associations with urate levels [whites: P = 10(-30), minor allele frequency (MAF) 0.11; blacks P = 10(-4), MAF 0.03] and gout (adjusted odds ratio 1.68 per risk allele, both races). Our data indicate that at least 10% of all gout cases in whites are attributable to this causal variant. With approximately 3 million US individuals suffering from often insufficiently treated gout, ABCG2 represents an attractive drug target. Our study completes the chain of evidence from association to causation and supports the common disease-common variant hypothesis in the etiology of gout.
Anzai,
New insights into renal transport of urate.
2007, Pubmed
Anzai,
New insights into renal transport of urate.
2007,
Pubmed Aulchenko,
GenABEL: an R library for genome-wide association analysis.
2007,
Pubmed Becker,
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
2005,
Pubmed Dehghan,
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.
2008,
Pubmed Donnelly,
Progress and challenges in genome-wide association studies in humans.
2008,
Pubmed Döring,
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.
2008,
Pubmed Doyle,
A multidrug resistance transporter from human MCF-7 breast cancer cells.
1998,
Pubmed Eckfeldt,
Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study.
1994,
Pubmed Enomoto,
Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease.
2005,
Pubmed Enomoto,
Molecular identification of a renal urate anion exchanger that regulates blood urate levels.
2002,
Pubmed
,
Xenbase Huls,
The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.
2008,
Pubmed Iribarren,
Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities.
1996,
Pubmed Krishnamurthy,
Role of ABCG2/BCRP in biology and medicine.
2006,
Pubmed Krishnan,
Gout in ambulatory care settings in the United States.
2008,
Pubmed Lawrence,
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.
2008,
Pubmed Li,
The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.
2007,
Pubmed Matsuo,
Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia.
2008,
Pubmed McCarthy,
Genome-wide association studies for complex traits: consensus, uncertainty and challenges.
2008,
Pubmed NULL,
The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.
1989,
Pubmed Polgar,
ABCG2: structure, function and role in drug response.
2008,
Pubmed Price,
Principal components analysis corrects for stratification in genome-wide association studies.
2006,
Pubmed Purcell,
PLINK: a tool set for whole-genome association and population-based linkage analyses.
2007,
Pubmed Rizwan,
Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.
2007,
Pubmed Schumacher,
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
2008,
Pubmed Van Aubel,
Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.
2005,
Pubmed Vitart,
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.
2008,
Pubmed
,
Xenbase Wallace,
Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.
2008,
Pubmed Yang,
Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study.
2005,
Pubmed Yates,
Complement C3 variant and the risk of age-related macular degeneration.
2007,
Pubmed Zeuthen,
Mobility of ions, sugar, and water in the cytoplasm of Xenopus oocytes expressing Na(+)-coupled sugar transporters (SGLT1).
2002,
Pubmed
,
Xenbase
